Literature DB >> 1475365

Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors.

P T Männistö1, I Ulmanen, K Lundström, J Taskinen, J Tenhunen, C Tilgmann, S Kaakkola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1475365     DOI： 10.1007/978-3-0348-7144-0_9

Source DB:  PubMed          Journal:  Prog Drug Res        ISSN： 0071-786X


× No keyword cloud information.
  29 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Authors:  H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

3.  Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers.

Authors:  Song Guo; Da Fang Chen; Dong Feng Zhou; Hong Qiang Sun; Gui Ying Wu; Colin N Haile; Therese A Kosten; Thomas R Kosten; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2007-01-06       Impact factor: 4.530

4.  The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.

Authors:  M Gerlach; A Y Xiao; W Kuhn; R Lehnfeld; P Waldmeier; K H Sontag; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

5.  Is impaired dopaminergic function associated with mobility capacity in older adults?

Authors:  Simon Moskowitz; David W Russ; Leatha A Clark; Nathan P Wages; Dustin R Grooms; Adam J Woods; Julie Suhr; Janet E Simon; Andrew O'Shea; Cody R Criss; Paolo Fadda; Brian C Clark
Journal:  Geroscience       Date:  2020-11-24       Impact factor: 7.713

6.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 7.  Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.

Authors:  Zhiguo Ma; Hongming Liu; Baojian Wu
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

8.  Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice.

Authors:  M Käenmäki; A Tammimäki; J A Garcia-Horsman; T Myöhänen; N Schendzielorz; M Karayiorgou; J A Gogos; P T Männistö
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 9.  Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?

Authors:  T Müller; W Kuhn; H Przuntek
Journal:  J Neural Transm Gen Sect       Date:  1993

10.  Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog.

Authors:  T Wikberg; P Ottoila; J Taskinen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Oct-Dec       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.